Accelerate

Accelerate the development of your combination products by shifting your focus to residual asset-specific requirements, while utilizing an intelligent, connected platform to standardize the core framework. This strategic approach increases overall reliability and significantly minimizes uncertainty before you commit to high-stakes, expensive clinical studies.

• Complete 90% of your drug development tasks ahead of time using a ready-to-use platform, leaving only the final 10% of asset-specific work for the project phase.
• Prepare your submission documentation content in advance within the platform to expedite the completion of final asset-specific details.
• Quickly adapt and reuse your entire documentation package as you move from one clinical study phase to the next using a consistent platform structure.

• Reduce development and regulatory requirements to the minimal needs of each clinical study phase
• Accelerate by letting your development team focus on the residual asset specific requirements
• Use suitable bracketing approaches to develop faster
• Streamline your development and regulatory focus by reducing the requirements to the minimal needs for each specific clinical study phase.
• Boost development speed by standardized components and documentation covering the reduced requirements.
• Implement optimized bracketing strategies to compress timelines and bring products to market faster.

• Utilize the harmonized requirements of your partner network to define all asset-specific needs concurrently and efficiently.
• Gain immediate access to documentation and components that have already been pre-developed by your partners.
• Seamlessly integrate your project into the pre-aligned activity schedules and timelines established by your partner network.